Table 2.
Proportion (%) of treatment-naïve and non-treatment-naïve patients experiencing greater than 5, 10 or 15 best corrected visual acuity (BCVA) letter gains or losses at Month 12 (M12) and Month 24 (M24).
| Treatment-naïve | Non-treatment-naïve | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Letter Change | Proportion of patients n (%) | Number of injections Mean (SD) | r | p-value | Proportion of patients n (%) | Number of injections Mean (SD) | r | p-value | ||
| M12 | All Patients | 388 (100) | - | - | - | 169 (100) | - | - | - | |
| Patients Receiving IVT-AFL | 388 (100) | 6.4 (2.1) | - | - | 169 (100) | 6.0 (2.4) | - | - | ||
| Gain | ≥ 5 | 156 (40.2) | 6.4 (1.9) | 0.19 | 0.02 | 51 (30.2) | 6.6 (2.4) | 0.00 | 0.97 | |
| ≥ 10 | 78 (20.1) | 6.5 (2.1) | 0.28 | 0.01 | 25 (14.8) | 6.8 (2.6) | −0.02 | 0.93 | ||
| ≥ 15 | 34 (8.8) | 6.8 (2.2) | 0.44 | 0.01 | 8 (4.7) | 6.9 (2.2) | −0.05 | 0.91 | ||
| Loss | ≥ 5 | 64 (16.5) | 6.4 (2.1) | 0.01 | 0.94 | 42 (24.9) | 5.6 (2.4) | −0.07 | 0.65 | |
| ≥ 10 | 38 (9.8) | 6.5 (2.0) | 0.05 | 0.77 | 24 (14.2) | 5.7 (2.1) | −0.15 | 0.49 | ||
| ≥ 15 | 23 (5.9) | 6.7 (2.2) | 0.20 | 0.36 | 9 (5.3) | 6.1 (2.6) | −0.15 | 0.71 | ||
| M24 | All Patients | 326 (100) | - | - | - | 135 (100) | - | - | - | |
| Patients Receiving IVT-AFL | 241 (73.9) | 3.7 (2.3) | - | - | 106 (78.5) | 4.3 (2.5) | - | - | ||
| Gain | ≥ 5 | 124 (38.0) | 3.6 (2.1) | 0.08 | 0.42 | 43 (31.9) | 4.5 (2.5) | −0.04 | 0.83 | |
| ≥ 10 | 54 (16.6) | 3.7 (2.3) | 0.18 | 0.26 | 20 (14.8) | 4.7 (2.0) | −0.18 | 0.47 | ||
| ≥ 15 | 27 (8.3) | 4.1 (2.4) | 0.02 | 0.92 | 9 (6.7) | 4.4 (2.0) | −0.30 | 0.51 | ||
| Loss | ≥ 5 | 85 (26.1) | 3.7 (2.3) | 0.03 | 0.81 | 39 (28.9) | 4.7 (2.6) | 0.14 | 0.47 | |
| ≥ 10 | 50 (15.3) | 3.6 (2.2) | 0.01 | 0.96 | 25 (18.5) | 4.2 (2.1) | 0.09 | 0.73 | ||
| ≥ 15 | 24 (7.4) | 3.3 (1.8) | −0.18 | 0.45 | 17 (12.6) | 4.2 (2.2) | 0.09 | 0.78 | ||
The mean (SD) number of intravitreal aflibercept injections for each subgroup is provided based on those patients receiving intravitreal aflibercept injections in each year. The correlation between letter gain or loss and the number of intravitreal aflibercept is represented by correlation coefficient (r) and associated p-value. The ‘All Patients’ cohort size and mean number of injections administered in year 1 (M12) and year 2 (M24) for each cohort have been included for comparison.